We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-19.31%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
-$863M
Cap. Flow
-$385M
Cap. Flow %
-27.93%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$36.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$359M
2
SANA icon
Sana Biotechnology
SANA
+$44.5M
3
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$18M
4
AXLA
Axcella Health Inc. Common Stock
AXLA
+$24

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$998M 72.47%
9,666,038
-3,220,705
-25% -$359M
SANA icon
2
Sana Biotechnology
SANA
$885M
$96.8M 7.02%
25,001,856
-8,288,162
-25% -$44.5M
FHTX icon
3
Foghorn Therapeutics
FHTX
$285M
$63.4M 4.6%
12,674,120
– –
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$62.8M 4.56%
29,225,579
– –
MCRB icon
5
Seres Therapeutics
MCRB
$48.1M
$55M 3.99%
1,155,852
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.67B
$54M 3.92%
2,619,968
– –
EVLO
7
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$31.1M 2.26%
7,932,624
+5,411,255
+215% +$36.9M
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
$12.2M 0.89%
1,170,059
-3
-0% -$24
SYRS
9
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.93M 0.29%
993,848
– –
SGTX
10
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
– –
-797,720
Closed -$18M

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q3 2023 Portfolio in Review

As of Q3 2023, Flagship Pioneering held 10 positions worth $1.38B, down 39% from $2.24B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering withdrew a net $385M in Q3 2023, closing 1 position and reducing 3 holdings. Its most notable exit was Sigilon Therapeutics, Inc. Common Stock, an estimated $18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Flagship Pioneering added an estimated $36.9M to Evelo Biosciences, Inc. Common Stock.

  • Flagship Pioneering added most to Evelo Biosciences, Inc. Common Stock in Q3 2023, an estimated $36.9M increase.
  • Flagship Pioneering's biggest Q3 2023 reduction was Moderna, cutting an estimated $359M.
  • Flagship Pioneering fully exited Sigilon Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $18M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $1.38B portfolio in Q3 2023.
  • Flagship Pioneering opened 0 new positions and closed 1 in Q3 2023.
  • Flagship Pioneering's portfolio value fell 39% quarter-over-quarter to $1.38B.

Based on Flagship Pioneering's 13F filing for Q3 2023, filed 14 Nov 2023.